You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
步長製藥(603858.SH):宣肺敗毒顆粒第一季度銷售收入達1.81億元
格隆匯 06-01 13:51

格隆匯6月1日丨有投資者向步長製藥(603858.SH)提問:請問宣肺敗毒顆粒今年的銷量如何?前期擴產能的項目建設是否還繼續,事後諸葛亮的決策是否有人檢討?

步長製藥回覆:尊敬的投資者您好,感謝您對公司的關注。宣肺敗毒顆粒2023年第一季度銷售收入達1.81億元。公司將根據市場需求對宣肺敗毒顆粒現有產能進行優化,公司將嚴格按照《上海證券交易所股票上市規則》及行業指引等相關規定及時披露項目進展情況,詳情請關注公司相關公吿。謝謝。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account